GLPwatch
Papers (10409)
Page 114 of 174, ranked by citation count.
- Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
- Analysis of clinical studies on clozapine from 2012-2022.
- Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.
- Sodium glycocholate liposome encapsulated semaglutide increases oral bioavailability by promoting intestinal absorption.
- Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos.
- Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.
- Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12)12-Exendin-4 PET/CT.
- HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
- Effects of exendin-4 on colonic motility in rats and its underlying mechanism.
- Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
- Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study.
- Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.
- The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes.
- Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!
- iGlarLixi for type 2 diabetes: a systematic review and meta-analysis.
- Regulation of feeding and therapeutic application of bioactive peptides.
- [Current State of Pharmacotherapy in Obesity].
- Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: iatrogenic adrenal insufficiency.
- Liraglutide for weight loss in obese people.
- A two-step method preparation of semaglutide through solid-phase synthesis and inclusion body expression.
- Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.
- Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.
- Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.
- The efficacy of liraglutide combined with intragastric balloon on weight loss.
- Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis.
- Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
- Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.
- [Liraglutide attenuates myocardial ischemia/reperfusion injury possibly through reducing cardiomyocytes apoptosis and oxidation in rats].
- Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia.
- REWIND to fast forward: time to revisit stroke prevention in type 2 diabetes?
- Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
- Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study.
- Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist.
- The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.
- The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes.
- The Expression of RAAS Key Receptors, <i>Agtr2</i> and <i>Bdkrb1</i>, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome.
- Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
- Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis.
- Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
- The pursuit of optimal semaglutide dosing in type 2 diabetes continues.
- Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
- Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.
- Paradoxical new-onset psoriasiform dermatitis associated with exenatide administration.
- Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.
- Additive Effects of Exenatide, Glucose-insulin-potassium, and Remote Ischemic Conditioning Against Reperfusion Ventricular Arrhythmias in Pigs.
- Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
- Oral Semaglutide Led to Similar Weight Loss as Injection, Company Says.
- Liraglutide for Adolescents with Obesity.
- Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study.
- Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
- Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy.
- Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.
- UK regulator warns public after seizing hundreds of fake Ozempic pens.
- Tirzepatide, a novel, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist for the ongoing diabesity epidemic: the dawn of a new era?
- PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.
- Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
- Enhancing bile tolerance of Lactobacilli is involved in the hypolipidemic effects of liraglutide.
- Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years.
- 2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide.
- The GLP-1 Receptor Agonist Liraglutide Decreases Primary Bile Acids and Serotonin in the Colon Independently of Feeding in Mice.